Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase NA 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Dermatologic 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × regramostim × Clear all
NCT02411786 2021-02-04

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

University of Wisconsin, Madison

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT04072900 2020-04-28

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Xiangya Hospital of Central South University

Phase 1 Unknown
30 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00582140 2019-11-19

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

University of Wisconsin, Madison

Phase 1 Completed
22 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡